Skip to main page content
U.S. flag

An official website of the United States government

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

2020
2025

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2020 1
2021 4
2022 1
2023 2
2024 3
2025 0

Publication date

Text availability

Article attribute

Article type

Additional filters

Search Results

11 results

Results by year

Filters applied: . Clear all
Page 1
Cellular reprogramming in vivo initiated by SOX4 pioneer factor activity.
Katsuda T, Sussman JH, Ito K, Katznelson A, Yuan S, Takenaka N, Li J, Merrell AJ, Cure H, Li Q, Rasool RU, Asangani IA, Zaret KS, Stanger BZ. Katsuda T, et al. Nat Commun. 2024 Feb 26;15(1):1761. doi: 10.1038/s41467-024-45939-z. Nat Commun. 2024. PMID: 38409161 Free PMC article.
NSD2 is a requisite subunit of the AR/FOXA1 neo-enhanceosome in promoting prostate tumorigenesis.
Parolia A, Eyunni S, Verma BK, Young E, Liu L, George J, Aras S, Das CK, Mannan R, Rasool RU, Luo J, Carson SE, Mitchell-Velasquez E, Liu Y, Xiao L, Gajjala PR, Jaber M, Wang X, He T, Qiao Y, Pang M, Zhang Y, Alhusayan M, Cao X, Tavana O, Hou C, Wang Z, Ding K, Chinnaiyan AM, Asangani IA. Parolia A, et al. bioRxiv [Preprint]. 2024 Mar 29:2024.02.22.581560. doi: 10.1101/2024.02.22.581560. bioRxiv. 2024. Update in: Nat Genet. 2024 Oct;56(10):2132-2143. doi: 10.1038/s41588-024-01893-6 PMID: 38464251 Free PMC article. Updated. Preprint.
NSD2 is a requisite subunit of the AR/FOXA1 neo-enhanceosome in promoting prostate tumorigenesis.
Parolia A, Eyunni S, Verma BK, Young E, Liu Y, Liu L, George J, Aras S, Das CK, Mannan R, Ur Rasool R, Mitchell-Velasquez E, Mahapatra S, Luo J, Carson SE, Xiao L, Gajjala PR, Venkatesh S, Jaber M, Wang X, He T, Qiao Y, Pang M, Zhang Y, Tien JC, Louw M, Alhusayan M, Cao X, Su F, Tavana O, Hou C, Wang Z, Ding K, Chinnaiyan AM, Asangani IA. Parolia A, et al. Nat Genet. 2024 Oct;56(10):2132-2143. doi: 10.1038/s41588-024-01893-6. Epub 2024 Sep 9. Nat Genet. 2024. PMID: 39251788 Free PMC article.
Toppling the HAT to Treat Lethal Prostate Cancer.
Rasool RU, Natesan R, Asangani IA. Rasool RU, et al. Cancer Discov. 2021 May;11(5):1011-1013. doi: 10.1158/2159-8290.CD-21-0184. Cancer Discov. 2021. PMID: 33947717
Physiological reprogramming in vivo mediated by Sox4 pioneer factor activity.
Katsuda T, Sussman J, Ito K, Katznelson A, Yuan S, Li J, Merrell AJ, Takenaka N, Cure H, Li Q, Rasool RU, Asangani IA, Zaret KS, Stanger BZ. Katsuda T, et al. bioRxiv [Preprint]. 2023 Feb 14:2023.02.14.528556. doi: 10.1101/2023.02.14.528556. bioRxiv. 2023. Update in: Nat Commun. 2024 Feb 26;15(1):1761. doi: 10.1038/s41467-024-45939-z PMID: 36824858 Free PMC article. Updated. Preprint.
Loss of LCMT1 and biased protein phosphatase 2A heterotrimerization drive prostate cancer progression and therapy resistance.
Rasool RU, O'Connor CM, Das CK, Alhusayan M, Verma BK, Islam S, Frohner IE, Deng Q, Mitchell-Velasquez E, Sangodkar J, Ahmed A, Linauer S, Mudrak I, Rainey J, Zawacki KP, Suhan TK, Callahan CG, Rebernick R, Natesan R, Siddiqui J, Sauter G, Thomas D, Wang S, Taylor DJ, Simon R, Cieslik M, Chinnaiyan AM, Busino L, Ogris E, Narla G, Asangani IA. Rasool RU, et al. Nat Commun. 2023 Aug 29;14(1):5253. doi: 10.1038/s41467-023-40760-6. Nat Commun. 2023. PMID: 37644036 Free PMC article.
Oncofusion-driven de novo enhancer assembly promotes malignancy in Ewing sarcoma via aberrant expression of the stereociliary protein LOXHD1.
Deng Q, Natesan R, Cidre-Aranaz F, Arif S, Liu Y, Rasool RU, Wang P, Mitchell-Velasquez E, Das CK, Vinca E, Cramer Z, Grohar PJ, Chou M, Kumar-Sinha C, Weber K, Eisinger-Mathason TSK, Grillet N, Grünewald TGP, Asangani IA. Deng Q, et al. Cell Rep. 2022 Jun 14;39(11):110971. doi: 10.1016/j.celrep.2022.110971. Cell Rep. 2022. PMID: 35705030 Free PMC article.
11 results